[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100651822":3},{"organization":4,"outcomesModule":7,"designInfo":23,"detailedDescription":31,"studyPopulation":28,"armGroups":32,"interventions":45,"overallOfficials":59,"centralContacts":63,"locations":72,"responsibleParty":94,"collaborators":28,"id":97,"slug":98,"hasResults":99,"nctId":100,"briefTitle":101,"officialTitle":101,"acronym":28,"eligibilityCriteria":102,"healthyVolunteers":99,"sex":103,"minAge":104,"maxAge":105,"enrollmentInfo":106,"targetDuration":28,"studyType":109,"phases":110,"briefSummary":112,"conditions":113,"keywords":115,"overallStatus":75,"whyStopped":28,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":130},{"fullName":5,"class":6},"King Edward Medical University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":18},[9],{"measure":10,"description":11,"timeFrame":12},"Survival\u002FMortality rate","Proportion of patients alive (survival) vs. deceased (mortality) at day 28.","28 days after enrollment",[14],{"measure":15,"description":16,"timeFrame":17},"Length of hospital stay","Lenght of Hospital stay from admission to death\u002Fdischarge.","From admission to discharge or death (up to 28 days)",[19],{"measure":20,"description":21,"timeFrame":22},"Change in Liver Function Tests","Improvement\u002FDecline in liver function tests from Baseline to day i.e Change in bilirubin, albumin, INR, AST, ALT from baseline to day 4.","4 days",{"allocation":24,"interventionModel":25,"interventionModelDescription":26,"primaryPurpose":27,"observationalModel":28,"timePerspective":28,"maskingInfo":29},"RANDOMIZED","PARALLEL","Participants will be randomly allocated 1:1 to receive either oral\u002FNG N-acetylcysteine plus standard supportive care, or standard supportive care alone, and followed in parallel for outcome assessment through day 28.","TREATMENT",null,{"masking":30,"maskingDescription":28,"whoMasked":28},"NONE","Acute liver failure carries high mortality, and in resource-limited settings like Pakistan, liver transplantation is often inaccessible, making pharmacologic adjuncts to supportive care important. Prior studies (Nabi et al. 2017; Mumtaz et al. 2009; Parkas et al. 2016) suggest oral NAC may improve survival and shorten hospital stay in non-acetaminophen ALF, though evidence remains limited. This trial will randomly assign eligible patients via computer-generated randomization to receive oral\u002FNG NAC (140 mg\u002Fkg every 4 hours for 16 hours, then every 6-8 hours, continued for 3 days) plus standard supportive care, or standard supportive care alone. Standard care includes glucose monitoring, prophylactic antimicrobials, proton pump inhibitors, fluid\u002Felectrolyte management, anti-encephalopathy measures as needed, and fresh frozen plasma for bleeding. Patients will be followed for up to 28 days.",[33,39],{"label":34,"type":35,"description":36,"interventionNames":37},"NAC Group","EXPERIMENTAL","Oral or nasogastric N-acetylcysteine, 140 mg\u002Fkg every 4 hours for the first 16 hours, then every 6-8 hours, continued for 3 days, plus standard supportive care.\n\nIntervention: Drug: N-acetylcysteine",[38],"Drug: N Acetyl Cysteine",{"label":40,"type":41,"description":42,"interventionNames":43},"Control Group","ACTIVE_COMPARATOR","Standard supportive care protocol for acute liver failure (glucose control, antimicrobials, PPIs, fluid\u002Felectrolyte management, antiencephalopathy measures, FFP as needed). Intervention: Other: Standard Supportive Care",[44],"Other: Standard supportive care",[46,53],{"type":47,"name":48,"description":49,"armGroupLabels":50,"otherNames":51},"DRUG","N Acetyl Cysteine","Oral or nasogastric N-acetylcysteine administered at 140 mg\u002Fkg every 4 hours for the first 16 hours, followed by 140 mg\u002Fkg every 6-8 hours, continued for a total duration of 3 days, given in addition to standard supportive care.",[34],[52],"NAC",{"type":6,"name":54,"description":55,"armGroupLabels":56,"otherNames":57},"Standard supportive care","Standard supportive care protocol for acute liver failure (glucose control, antimicrobials, PPIs, fluid\u002Felectrolyte management, anti-encephalopathy measures, FFP as needed).",[40],[58],"Supportive care protocol for liver failure",[60],{"name":61,"affiliation":5,"role":62},"Somia Iqtadar, FCPS","PRINCIPAL_INVESTIGATOR",[64,69],{"name":61,"role":65,"phone":66,"phoneExt":67,"email":68},"CONTACT","+92 42 99211129","331","somia.iqtadar@gmail.com",{"name":70,"role":65,"phone":66,"phoneExt":67,"email":71},"Zaeem Ahmad, MBBS","zaeem.ahmad344@gmail.com",[73],{"facility":74,"status":75,"city":76,"state":77,"zip":78,"country":79,"countryCode":80,"cosmosGeoPoint":81,"geoPoint":86,"contacts":87},"King Edward Medical University\u002FMayo Hospital Lahore","RECRUITING","Lahore","Punjab Province","54000","Pakistan","PK",{"type":82,"coordinates":83},"Point",[84,85],74.35071,31.558,{"lat":85,"lon":84},[88,90,91,92],{"name":89,"role":65,"phone":66,"phoneExt":67,"email":71},"Israr Toor, FCPS",{"name":28,"role":65,"phone":28,"phoneExt":28,"email":71},{"name":70,"role":62,"phone":28,"phoneExt":28,"email":28},{"name":61,"role":93,"phone":28,"phoneExt":28,"email":28},"SUB_INVESTIGATOR",{"type":62,"investigatorFullName":95,"investigatorTitle":96,"investigatorAffiliation":5,"oldNameTitle":28,"oldOrganization":28},"somia iqtadar","Associate Professor","100651822","role-of-n-acetylcysteine-in-non-acetaminophen-induced-liver-failure-100651822",false,"NCT07765823","Role of N-Acetylcysteine in Non-Acetaminophen-Induced Liver Failure","Inclusion Criteria:\n\n* Male or female, aged 18-60 years\n* Diagnosed with non-acetaminophen- induced acute hepatic failure (per operational definition\u002FEASL criteria)\n* Etiology other than acetaminophen overdose (viral hepatitis HAV\u002FHBV\u002FHEV, non-acetaminophen drug-induced liver injury, or idiopathic)\n* No NAC treatment received for current episode prior to enrollment\n\nExclusion Criteria:\n\n* History of chronic liver disease or cirrhosis\n* Prior severe cardiac, renal, neurological, or infectious disease that could confound outcomes\n* Prior liver transplant or current transplant candidacy\n* Known allergy\u002Fcontraindication to NAC\n* Pregnant women.","ALL","18 Years","60 Years",{"count":107,"type":108},62,"ESTIMATED","INTERVENTIONAL",[111],"NA","This randomized controlled trial evaluates whether oral N-acetylcysteine (NAC), given alongside standard supportive care, improves survival and reduces mortality in patients with non-acetaminophen-induced acute liver failure (ALF), compared to supportive care alone. Secondary objectives are to assess NAC's effect on length of hospital stay and improvement in liver function tests. Sixty-two adult patients (18-60 years) will be randomized 1:1 to NAC or control, with outcomes assessed at 28 days (survival\u002Fmortality) and day 4 (liver function tests).",[114],"Acute Liver Failure",[116,117,118,119,120],"hepatic failure","acute liver failure","acetylcysteine","randomized controlled trial","supportive care","2026-08-16",{"date":123,"type":124},"2026-08-19","ACTUAL",{"date":126,"type":124},"2026-07-16",{"date":128,"type":108},"2026-10-17",{"name":5,"class":6},1]